{"id":"NCT04567329","sponsor":"Bausch & Lomb Incorporated","briefTitle":"Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)","officialTitle":"A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-11-18","primaryCompletion":"2021-08-30","completion":"2021-08-30","firstPosted":"2020-09-28","resultsPosted":"2024-08-19","lastUpdate":"2024-08-19"},"enrollment":620,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Disease"],"interventions":[{"type":"DRUG","name":"NOV03","otherNames":[]},{"type":"DRUG","name":"Saline Solution","otherNames":[]}],"arms":[{"label":"NOV03","type":"EXPERIMENTAL"},{"label":"Saline solution","type":"PLACEBO_COMPARATOR"}],"summary":"The objectives of this trial are to assess the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).","primaryOutcome":{"measure":"Change From Baseline in Total Corneal Fluorescein Staining Score (NEI Scale) in the Study Eye at Day 57","timeFrame":"Assessed at Day 57","effectByArm":[{"arm":"NOV03","deltaMin":-2.3,"sd":2.8},{"arm":"Saline Solution","deltaMin":-1.1,"sd":2.9}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":35,"countries":["United States"]},"refs":{"pmids":["39564145","36948372"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":311},"commonTop":["Eye disorder","Hyperaemia"]}}